Skip to main content

Table 1 Baseline characteristics of 1307 patients who had molecular alterations

From: Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine

CharacteristicN (%)Matched therapy (%)Non-matched therapy (%)p
N = 711N = 596
Age, years   .38
 < 60708 (54.2)393 (55.3)315 (52.9) 
 ≥ 60599 (45.8)318 (44.7)281 (47.1) 
Sex   .67
 Female802 (61.4)440 (61.9)362 (6.7) 
 Male505 (38.6)271 (38.1)234 (39.3) 
Number of prior therapies   .41
 ≤ 3637 (48.7)354 (49.8)283 (47.5) 
 > 3670 (51.3)357 (5.2)313 (52.5) 
Performance status   .27
 0–11211 (92.7)664 (93.4)547 (91.8) 
 > 196 (7.3)47 (6.6)49 (8.2) 
Platelet count, × 109/L   .815
 ≤ 4401254 (95.9)683 (96.1)571 (95.8) 
 > 44053 (4.1)28 (3.9)25 (4.2) 
Number of metastatic sites   .61
 0-2867 (66.3)476 (66.9)391 (65.6) 
 > 2440 (33.7)235 (33.1)205 (34.4) 
Liver metastases   .03
 No839 (64.2)475 (66.8)364 (61.1) 
 Yes468 (35.8)236 (33.2)232 (38.9) 
Lactate dehydrogenase, IU/L   < .001
 ≤ 618856 (65.5)499 (7.2)357 (59.9) 
 > 618451 (34.5)212 (29.8)239 (4.1) 
Albumin, g/dL   .16
 < 3.51185 (9.7)652 (91.7)533 (89.4) 
 ≥ 3.5122 (9.3)59 (8.3)63 (1.6) 
Tumor type   N/A*
 Breast177 (13.5)120 (16.9)57 (9.6) 
 Colorectal238 (18.2)90 (12.7)148 (24.8) 
 Endometrial55 (4.2)40 (5.6)15 (2.5) 
 Gastrointestinal, other79 (6.0)33 (4.6)46 (7.7) 
 Genitourinary, other35 (2.7)17 (2.4)18 (3.0) 
 Gynecological, other67 (5.1)35 (4.9)32 (5.4) 
 Head and neck69 (5.3)36 (5.1)33 (5.5) 
 Renal12 (.9)6 (.8)6 (.8) 
 Lung114 (8.7)71 (1.0)43 (7.2) 
 Melanoma155 (11.9)101 (14.2)54 (9.1) 
 Other55 (4.2)33 (4.6)22 (3.7) 
 Ovarian132 (1.1)59 (8.3)73 (12.3) 
 Pancreatic25 (1.9)7 (1.0)18 (3.0) 
 Sarcoma33 (2.5)19 (2.7)14 (2.4) 
 Thyroid61 (4.7)44 (6.2)17 (2.9) 
  1. *The distribution of tumor types is imbalanced between the two treatment groups; therefore, the p value is non-applicable